Contact Us: 01282 426380
KM Financial Solutions | Woodford-backed biotech Prothena plunges as key drug fails
15352
post-template-default,single,single-post,postid-15352,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

Woodford-backed biotech Prothena plunges as key drug fails

22 Apr Woodford-backed biotech Prothena plunges as key drug fails

Posted at 13:57h in News by
0 Likes
LONDON, April 23 (Reuters) – Shares in Prothena, a
biotech company backed by British investor Neil Woodford,
plunged 70 percent on Monday after its main drug for treating a
rare disease called AL amyloidosis failed in a crucial clinical
trial.

No Comments

Sorry, the comment form is closed at this time.